{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:22:46Z","timestamp":1778613766095,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12672-018-0352-7","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T02:07:05Z","timestamp":1540260425000},"page":"11-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro"],"prefix":"10.1007","volume":"10","author":[{"given":"Ashraf","family":"Khalil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Jameson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"issue":"2","key":"352_CR1","doi-asserted-by":"publisher","first-page":"FSO174","DOI":"10.4155\/fsoa-2016-0089","volume":"3","author":"R Bower","year":"2017","unstructured":"Bower R, Green VL, Kuvshinova E, Kuvshinov D, Karsai L, Crank ST, Stafford ND, Greenman J (2017) Maintenance of head and neck tumor on-chip: gateway to personalized treatment? Future Sci OA 3(2):FSO174","journal-title":"Future Sci OA"},{"key":"352_CR2","unstructured":"Ahn PH, Machtay M, Anne PR, Cognetti D, Keane WM, Wuthrick E, Dicker AP, Axelrod RS (2016) Phase I trial using induction cisplatin, docetaxel, 5-FU and erlotinib followed by cisplatin, bevacizumab and erlotinib with concurrent radiotherapy for advanced head and neck cancer. Am J Clin Oncol"},{"issue":"1","key":"352_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/10717544.2016.1236849","volume":"24","author":"J Yang","year":"2016","unstructured":"Yang J, Ju Z, Dong S (2016) Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer. Drug Deliv 24(1):792\u2013799","journal-title":"Drug Deliv"},{"issue":"3","key":"352_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jfma.2016.03.005","volume":"116","author":"HM Wang","year":"2017","unstructured":"Wang HM, Lin CY, Hsieh CH, Hsu CL, Fan KH, Chang JT, Huang SF, Kang CJ, Liao CT, Ng SH, Yen TC (2017) Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer. J Formos Med Assoc 116(3):185\u2013192","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"352_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","volume":"2","author":"SK Denduluri","year":"2015","unstructured":"Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, Luu HH (2015) Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2(1):13\u201325","journal-title":"Genes Dis"},{"issue":"5","key":"352_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ghir.2013.06.001","volume":"23","author":"KH Limesand","year":"2013","unstructured":"Limesand KH, Chibly AM, Fribley A (2013) Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res 23(5):135\u2013140","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"352_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.radonc.2010.03.009","volume":"96","author":"NK Taunk","year":"2010","unstructured":"Taunk NK, Goyal S, Moran MS, Yang Q, Parikh R, Haffty BG (2010) Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol 96(2):204\u2013208","journal-title":"Radiother Oncol"},{"issue":"7","key":"352_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.oraloncology.2011.05.005","volume":"47","author":"PC Lara","year":"2011","unstructured":"Lara PC, Bordon E, Rey A, Moreno M, Lloret M, Henriquez-Hernandez LA (2011) IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma. Oral Oncol 47(7):615\u2013619","journal-title":"Oral Oncol"},{"issue":"10","key":"352_CR9","first-page":"6694","volume":"7","author":"S Zhao","year":"2014","unstructured":"Zhao S, Qiu Z, He J, Li L, Li W (2014) Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis. Int J Clin Exp Pathol 7(10):6694\u20136704","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"352_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1634\/theoncologist.2007-0199","volume":"13","author":"PD Ryan","year":"2008","unstructured":"Ryan PD, Goss PE (2008) The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13(1):16\u201324","journal-title":"Oncologist"},{"key":"352_CR11","doi-asserted-by":"crossref","unstructured":"Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T (2017) Insulin-like growth factor (IGF) pathway targeting in cancer: role of the IGF axis and opportunities for future combination studies. Target Oncol","DOI":"10.1007\/s11523-017-0514-5"},{"issue":"5","key":"352_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5732\/cjc.012.10263","volume":"32","author":"HX Chen","year":"2013","unstructured":"Chen HX, Sharon E (2013) IGF-1R as an anti-cancer target\u2014trials and tribulations. Chin J Cancer 32(5):242\u2013252","journal-title":"Chin J Cancer"},{"issue":"17","key":"352_CR13","doi-asserted-by":"publisher","first-page":"29501","DOI":"10.18632\/oncotarget.15704","volume":"8","author":"X Qu","year":"2017","unstructured":"Qu X, Wu Z, Dong W, Zhang T, Wang L, Pang Z, Ma W, Du J (2017) Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy. Oncotarget 8(17):29501\u201329518","journal-title":"Oncotarget"},{"issue":"5","key":"352_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-08-1171","volume":"8","author":"PJ Beltran","year":"2009","unstructured":"Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ (2009) AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 8(5):1095\u20131105","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"352_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1517\/14712591003689980","volume":"10","author":"A Gualberto","year":"2010","unstructured":"Gualberto A (2010) Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 10(4):575\u2013585","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"352_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/157489212798357930","volume":"7","author":"ER King","year":"2012","unstructured":"King ER, Wong KK (2012) Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov 7(1):14\u201330","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"3","key":"352_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/0008-5472.CAN-10-2274","volume":"71","author":"J Gao","year":"2011","unstructured":"Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS (2011) Dual IGF-I\/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 71(3):1029\u20131040","journal-title":"Cancer Res"},{"key":"352_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fphar.2013.00030","volume":"4","author":"A Arcaro","year":"2013","unstructured":"Arcaro A (2013) Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol 4:30","journal-title":"Front Pharmacol"},{"issue":"9","key":"352_CR19","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1128\/JVI.00252-14","volume":"88","author":"A Sloutskin","year":"2014","unstructured":"Sloutskin A, Yee MB, Kinchington PR, Goldstein RS (2014) Varicella-zoster virus and herpes simplex virus 1 can infect and replicate in the same neurons whether co- or superinfected. J Virol 88(9):5079\u20135086","journal-title":"J Virol"},{"issue":"1","key":"352_CR20","first-page":"73","volume":"16","author":"AN Aznan","year":"2018","unstructured":"Aznan AN, Abdul Karim N, Wan Ngah WZ, Jubri Z (2018) Critical factors for lentivirus-mediated PRDX4 gene transfer in the HepG2 cell line. Oncol Lett 16(1):73\u201382","journal-title":"Oncol Lett"},{"issue":"11","key":"352_CR21","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1158\/1535-7163.MCT-11-0294","volume":"10","author":"MJ Jameson","year":"2011","unstructured":"Jameson MJ, Beckler AD, Taniguchi LE, Allak A, Vanwagner LB, Lee NG, Thomsen WC, Hubbard MA, Thomas CY (2011) Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther 10(11):2124\u20132134","journal-title":"Mol Cancer Ther"},{"key":"352_CR22","doi-asserted-by":"crossref","unstructured":"Khalil A, Jameson MJ (2017) The EGFR inhibitor gefitinib enhanced the response of human oral squamous cell carcinoma to cisplatin in vitro. Drugs R D","DOI":"10.1007\/s40268-017-0204-x"},{"issue":"2","key":"352_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1134\/S0006297917020067","volume":"82","author":"AA Khalil","year":"2017","unstructured":"Khalil AA, Jameson MJ (2017) Sodium Orthovanadate Inhibits Proliferation and Triggers Apoptosis in Oral Squamous Cell Carcinoma in vitro. Biochemistry (Mosc) 82(2):149\u2013155","journal-title":"Biochemistry (Mosc)"},{"issue":"4","key":"352_CR24","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1074\/jbc.M007526200","volume":"276","author":"MJ Horney","year":"2001","unstructured":"Horney MJ, Evangelista CA, Rosenzweig SA (2001) Synthesis and characterization of insulin-like growth factor (IGF)-1 photoprobes selective for the IGF-binding proteins (IGFBPS). Photoaffinity labeling of the IGF-binding domain on IGFBP-2. J Biol Chem 276(4):2880\u20132889","journal-title":"J Biol Chem"},{"key":"352_CR25","doi-asserted-by":"crossref","unstructured":"Quintanilha JCF, Visacri MB, Sousa VM, Bastos LB, Vaz CO, Guarnieri JPO, Amaral LS, Malaguti C, Lima CSP, Vercesi AE, Moriel P (2017) Cisplatin-induced human peripheral blood mononuclear cells\u2019 oxidative stress and nephrotoxicity in head and neck cancer patients: the influence of hydrogen peroxide. Mol Cell Biochem","DOI":"10.1007\/s11010-017-3162-2"},{"issue":"12","key":"352_CR26","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3760\/cma.j.issn.0366-6999.20140318","volume":"127","author":"T Wang","year":"2014","unstructured":"Wang T, Ge G, Ding Y, Zhou X, Huang Z, Zhu W, Shu Y, Liu P (2014) MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J (Engl) 127(12):2357\u20132362","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"352_CR27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2174\/1871520614666140528161318","volume":"14","author":"M Yang","year":"2014","unstructured":"Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding Y, Shu Y, Liu P (2014) miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem 14(6):884\u2013891","journal-title":"Anticancer Agents Med Chem"},{"issue":"4","key":"352_CR28","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s13277-014-2898-5","volume":"36","author":"M Zhuang","year":"2015","unstructured":"Zhuang M, Shi Q, Zhang X, Ding Y, Shan L, Shan X, Qian J, Zhou X, Huang Z, Zhu W, Ding Y, Cheng W, Liu P, Shu Y (2015) Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Tumour Biol 36(4):2737\u20132745","journal-title":"Tumour Biol"},{"issue":"35","key":"352_CR29","doi-asserted-by":"publisher","first-page":"56826","DOI":"10.18632\/oncotarget.10862","volume":"7","author":"CH O\u2019Flanagan","year":"2016","unstructured":"O\u2019Flanagan CH, O\u2019Shea S, Lyons A, Fogarty FM, McCabe N, Kennedy RD, O\u2019Connor R (2016) IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin. Oncotarget 7(35):56826\u201356,841","journal-title":"Oncotarget"},{"issue":"6","key":"352_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1745-7270.2008.00429.x","volume":"40","author":"A Dong","year":"2008","unstructured":"Dong A, Kong M, Ma Z, Qian J, Cheng H, Xu X (2008) Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells. Acta Biochim Biophys Sin (Shanghai) 40(6):497\u2013504","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"4","key":"352_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00432-007-0314-x","volume":"134","author":"J Niu","year":"2008","unstructured":"Niu J, Li XN, Qian H, Han Z (2008) siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells. J Cancer Res Clin Oncol 134(4):503\u2013513","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"352_CR32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cellbi.2006.09.021","volume":"31","author":"J Niu","year":"2007","unstructured":"Niu J, Xu Z, Li XN, Han Z (2007) siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53. Cell Biol Int 31(2):156\u2013164","journal-title":"Cell Biol Int"},{"issue":"1","key":"352_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3109\/02841860903334429","volume":"49","author":"K Yavari","year":"2010","unstructured":"Yavari K, Taghikhani M, Maragheh MG, Mesbah-Namin SA, Babaei MH, Arfaee AJ, Madani H, Mirzaei HR (2010) SiRNA-mediated IGF-1R inhibition sensitizes human colon cancer SW480 cells to radiation. Acta Oncol 49(1):70\u201375","journal-title":"Acta Oncol"},{"issue":"16","key":"352_CR34","first-page":"5073","volume":"63","author":"EK Maloney","year":"2003","unstructured":"Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blattler WA, Chittenden T, Singh R (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63(16):5073\u20135083","journal-title":"Cancer Res"},{"issue":"2","key":"352_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.cr.7290075","volume":"11","author":"HZ Sun","year":"2001","unstructured":"Sun HZ, Wu SF, Tu ZH (2001) Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res 11(2):107\u2013115","journal-title":"Cell Res"},{"issue":"3","key":"352_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1046\/j.1464-410X.2003.04061.x","volume":"91","author":"GO Hellawell","year":"2003","unstructured":"Hellawell GO, Ferguson DJ, Brewster SF, Macaulay VM (2003) Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 91(3):271\u2013277","journal-title":"BJU Int"},{"issue":"7","key":"352_CR37","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1158\/0008-5472.CAN-08-3153","volume":"69","author":"N Eckstein","year":"2009","unstructured":"Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S, Napierski I, Hamacher A, Kassack MU, Budczies J, Beier M, Dietel M, Royer-Pokora B, Denkert C, Royer HD (2009) Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 69(7):2996\u20133003","journal-title":"Cancer Res"},{"issue":"1","key":"352_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.dnarep.2008.09.003","volume":"8","author":"WP Roos","year":"2009","unstructured":"Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, Zdzienicka MZ, Kaina B (2009) Brca2\/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) 8(1):72\u201386","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"352_CR39","doi-asserted-by":"publisher","first-page":"e0117745","DOI":"10.1371\/journal.pone.0117745","volume":"10","author":"S Heskamp","year":"2015","unstructured":"Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Wauters CA, Strobbe LJ, Mandigers CM, Bult P, Oyen WJ, van der Graaf WT, van Laarhoven HW (2015) Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. PLoS One 10(2):e0117745","journal-title":"PLoS One"},{"issue":"2","key":"352_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1470-2045(09)70354-7","volume":"11","author":"D Olmos","year":"2010","unstructured":"Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing\u2019s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11(2):129\u2013135","journal-title":"Lancet Oncol"},{"issue":"34","key":"352_CR41","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","volume":"29","author":"AS Pappo","year":"2010","unstructured":"Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH (2010) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29(34):4541\u20134547","journal-title":"J Clin Oncol"},{"issue":"34","key":"352_CR42","doi-asserted-by":"publisher","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","volume":"27","author":"AW Tolcher","year":"2009","unstructured":"Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27(34):5800\u20135807","journal-title":"J Clin Oncol"},{"issue":"34","key":"352_CR43","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1200\/JCO.2011.36.6799","volume":"29","author":"SS Ramalingam","year":"2011","unstructured":"Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP, Novello S, Eberhardt WE, Crino L, Habben K, Liu L, Janne PA, Brownstein CM, Reck M (2011) Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 29(34):4574\u20134580","journal-title":"J Clin Oncol"},{"issue":"12","key":"352_CR44","doi-asserted-by":"publisher","first-page":"djv258","DOI":"10.1093\/jnci\/djv258","volume":"107","author":"F Sclafani","year":"2015","unstructured":"Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ (2015) A randomized phase II\/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer. J Natl Cancer Inst 107(12):djv258","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"352_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ijc.30453","volume":"140","author":"F Sclafani","year":"2017","unstructured":"Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ (2017) Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II\/III trial. Int J Cancer 140(2):431\u2013439","journal-title":"Int J Cancer"},{"key":"352_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fendo.2015.00077","volume":"6","author":"LW Bowers","year":"2015","unstructured":"Bowers LW, Rossi EL, O\u2019Flanagan CH, deGraffenried LA, Hursting SD (2015) The role of the insulin\/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link. Front Endocrinol (Lausanne) 6:77","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"352_CR47","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/carcin\/bgv053","volume":"36","author":"OT Dale","year":"2015","unstructured":"Dale OT, Aleksic T, Shah KA, Han C, Mehanna H, Rapozo DC, Sheard JD, Goodyear P, Upile NS, Robinson M, Jones TM, Winter S, Macaulay VM (2015) IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer. Carcinogenesis 36(6):648\u2013655","journal-title":"Carcinogenesis"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-018-0352-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-018-0352-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-018-0352-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T17:24:44Z","timestamp":1720718684000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-018-0352-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1007\/s12672-018-0352-7","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"17 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}